scholarly article | Q13442814 |
P50 | author | Andre J van Wijnen | Q60974897 |
Gary S Stein | Q88625567 | ||
Simon M Cool | Q89748654 | ||
Victor Nurcombe | Q93333970 | ||
Zophia X H Lim | Q117270543 | ||
P2093 | author name string | Bina Rai | |
Wanjin Hong | |||
Christian Dombrowski | |||
James H Hui | |||
Torben Helledie | |||
David A Rider | |||
Ian Lee Hock Hin | |||
P2860 | cites work | Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. | Q50734767 |
Matrix-mediated retention of in vitro osteogenic differentiation potential and in vivo bone-forming capacity by human adult bone marrow-derived mesenchymal stem cells during ex vivo expansion. | Q51187329 | ||
FGF-2 enhances the mitotic and chondrogenic potentials of human adult bone marrow-derived mesenchymal stem cells. | Q51589137 | ||
Human first-trimester fetal MSC express pluripotency markers and grow faster and have longer telomeres than adult MSC. | Q52001009 | ||
Resampling methods for variance estimation of singular value decomposition analyses from microarray experiments. | Q52034437 | ||
Perivascular niche of postnatal mesenchymal stem cells in human bone marrow and dental pulp. | Q52107163 | ||
Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. | Q52119168 | ||
Bone formation by human postnatal bone marrow stromal stem cells is enhanced by telomerase expression. | Q52119170 | ||
Developmental Regulation of Neural Response to FGF-1 and FGF-2 by Heparan Sulfate Proteoglycan | Q52225676 | ||
Locally applied osteogenic predifferentiated progenitor cells are more effective than undifferentiated mesenchymal stem cells in the treatment of delayed bone healing. | Q52912019 | ||
Tumorigenic heterogeneity in cancer stem cells evolved from long-term cultures of telomerase-immortalized human mesenchymal stem cells. | Q53358865 | ||
Autocrine fibroblast growth factor 2 increases the multipotentiality of human adipose-derived mesenchymal stem cells. | Q54541100 | ||
Enrichment for STRO-1 expression enhances the cardiovascular paracrine activity of human bone marrow-derived mesenchymal cell populations | Q59696056 | ||
Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease | Q63197317 | ||
A Defined Medium and Substrate for Expansion of Human Mesenchymal Stromal Cell Progenitors That Enriches for Osteo- and Chondrogenic Precursors | Q63459914 | ||
Repair of large bone defects with the use of autologous bone marrow stromal cells | Q73482003 | ||
Tissue-engineered bone regeneration | Q74268240 | ||
Mesenchymal stem cells in osteobiology and applied bone regeneration | Q77902271 | ||
Characterization of nonexpanded mesenchymal progenitor cells from normal adult human bone marrow | Q81330304 | ||
Telomere measurement by quantitative PCR | Q24529938 | ||
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources | Q27860739 | ||
Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement | Q27861120 | ||
Heparan sulfate mediates the proliferation and differentiation of rat mesenchymal stem cells | Q28580650 | ||
Oncogenic pathway signatures in human cancers as a guide to targeted therapies | Q29615526 | ||
Pluripotency of mesenchymal stem cells derived from adult marrow | Q29617959 | ||
Singular value decomposition for genome-wide expression data processing and modeling | Q29618495 | ||
Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells | Q29618766 | ||
Identification of a subpopulation of rapidly self-renewing and multipotential adult stem cells in colonies of human marrow stromal cells | Q30454202 | ||
Differential exoprotease activities confer tumor-specific serum peptidome patterns | Q33230965 | ||
Differences between in vitro viability and differentiation and in vivo bone-forming efficacy of human mesenchymal stem cells cultured on PCL-TCP scaffolds | Q33650551 | ||
Heparan sulfate: growth control with a restricted sequence menu | Q34328757 | ||
SSEA-4 identifies mesenchymal stem cells from bone marrow | Q34576375 | ||
The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells | Q34704081 | ||
Mesenchymal stem cells and their potential as cardiac therapeutics | Q35830869 | ||
Human bone marrow mesenchymal stem cells in vivo | Q36994690 | ||
Long-term in vitro expansion alters the biology of adult mesenchymal stem cells | Q37269767 | ||
Optimizing mesenchymal stem cell-based therapeutics. | Q37604019 | ||
Mechanisms involved in the therapeutic properties of mesenchymal stem cells | Q37635499 | ||
Number and proliferative capacity of osteogenic stem cells are maintained during aging and in patients with osteoporosis | Q38300172 | ||
Structural modification of fibroblast growth factor-binding heparan sulfate at a determinative stage of neural development | Q38339362 | ||
Selection using the alpha-1 integrin (CD49a) enhances the multipotentiality of the mesenchymal stem cell population from heterogeneous bone marrow stromal cells | Q40095061 | ||
Epidermal growth factor as a candidate for ex vivo expansion of bone marrow-derived mesenchymal stem cells | Q40375826 | ||
Expression of the developmental markers STRO-1 and alkaline phosphatase in cultures of human marrow stromal cells: regulation by fibroblast growth factor (FGF)-2 and relationship to the expression of FGF receptors 1-4. | Q40865830 | ||
Human marrow stromal precursors are alpha 1 integrin subunit-positive | Q40866247 | ||
The growth factor requirements of STRO-1-positive human bone marrow stromal precursors under serum-deprived conditions in vitro | Q40994591 | ||
Development of novel monoclonal antibodies that define differentiation stages of human stromal (mesenchymal) stem cells | Q41864248 | ||
Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells | Q42482834 | ||
Osteogenic differentiation of purified, culture-expanded human mesenchymal stem cells in vitro | Q42529073 | ||
Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications | Q43898390 | ||
Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. | Q45859658 | ||
Propagation and senescence of human marrow stromal cells in culture: a simple colony-forming assay identifies samples with the greatest potential to propagate and differentiate | Q45863683 | ||
STRO-1, HOP-26 (CD63), CD49a and SB-10 (CD166) as markers of primitive human marrow stromal cells and their more differentiated progeny: a comparative investigation in vitro | Q45864121 | ||
The stimulation of healing within a rat calvarial defect by mPCL-TCP/collagen scaffolds loaded with rhBMP-2. | Q46151556 | ||
Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells | Q46284854 | ||
Molecular mechanisms of FGF-2 inhibitory activity in the osteogenic context of mouse adipose-derived stem cells (mASCs). | Q46638492 | ||
P433 | issue | 11 | |
P304 | page(s) | 1897-1910 | |
P577 | publication date | 2012-01-18 | |
P1433 | published in | Stem Cells and Development | Q15724421 |
P1476 | title | Heparan sulfate enhances the self-renewal and therapeutic potential of mesenchymal stem cells from human adult bone marrow | |
P478 | volume | 21 |
Q50865098 | A Versatile Protocol for Studying Calvarial Bone Defect Healing in a Mouse Model. |
Q38215555 | Advances in mesenchymal stem cell-based strategies for cartilage repair and regeneration |
Q38292089 | Affinity Selection of FGF2-Binding Heparan Sulfates for Ex Vivo Expansion of Human Mesenchymal Stem Cells |
Q37716635 | Cell-autonomous heparanase modulates self-renewal and migration in bone marrow-derived mesenchymal stem cells |
Q47095797 | Concise Review: Multifaceted Characterization of Human Mesenchymal Stem Cells for Use in Regenerative Medicine. |
Q33426878 | Effect of heparin on the biological properties and molecular signature of human mesenchymal stem cells |
Q37718020 | Establishing criteria for human mesenchymal stem cell potency |
Q46054367 | Exploiting Heparan Sulfate Proteoglycans in Human Neurogenesis-Controlling Lineage Specification and Fate |
Q42363800 | Heparan Sulfate: A Potential Candidate for the Development of Biomimetic Immunomodulatory Membranes |
Q64059120 | Heparin Differentially Impacts Gene Expression of Stromal Cells from Various Tissues |
Q37170068 | Identification and validation of multiple cell surface markers of clinical-grade adipose-derived mesenchymal stromal cells as novel release criteria for good manufacturing practice-compliant production |
Q34509764 | Immobilization of heparan sulfate on electrospun meshes to support embryonic stem cell culture and differentiation |
Q38395222 | Mesenchymal Stem/Stromal Cells in Liver Fibrosis: Recent Findings, Old/New Caveats and Future Perspectives |
Q33722683 | Microfluidic Screening Reveals Heparan Sulfate Enhances Human Mesenchymal Stem Cell Growth by Modulating Fibroblast Growth Factor-2 Transport |
Q58799277 | Periodontal reconstruction by heparan sulfate mimetic-based matrix therapy in -infected mice |
Q58676364 | Presentation of functional groups on self-assembled supramolecular peptide nanofibers mimicking glycosaminoglycans for directed mesenchymal stem cell differentiation |
Q60046880 | Recombinant Heparin-New Opportunities |
Q37634126 | XYLT1 mutations in Desbuquois dysplasia type 2. |
Search more.